Please login to the form below
progressive pulmonary fibrosis
This page shows the latest progressive pulmonary fibrosis news and features for those working in and with pharma, biotech and healthcare.
Boehringer Ingelheim enrols first patient in pulmonary fibrosis phase 3 trial
Boehringer Ingelheim has enrolled the first patient in its global phase 3 trial evaluating BI 1015550, an investigational phosphodiesterase 4B inhibitor, in patients with idiopathic pulmonary fibrosis (IPF), the company announced. ... New treatments for
Latest news
-
Boehringer Ingelheim’s pulmonary fibrosis treatment produces promising phase 2 data
Idiopathic pulmonary fibrosis (IPF) is regarded as being one of the more common types of progressive fibrosing interstitial lung diseases. ... Boehringer Ingelheim will begin a phase 3 clinical trial programme to continue investigating if BI 1015550
-
Orphan drugs in latest CHMP recommendations
The other orphan medicine recommended by the CHMP was Boehringer's Ofev, which received a positive opinion for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive scarring of the lungs
-
Intermune supports awareness efforts for IPF
Biotech firm Intermune last week lent its backing to IPF World Week to support the awareness campaign for idiopathic pulmonary fibrosis (IPF). ... In Europe, some 100 initiatives took place in IPF centres of excellence, while a number of US initiatives
More from news
Approximately 1 fully matching, plus 3 partially matching documents found.
Latest Intelligence
-
Pharma deals during August 2014
This brings a much needed boost to its respiratory portfolio, which currently consists of Pulmozyme (cystic fibrosis) and Xolair (severe asthma) and products in clinical development, eg lebrikizumab (severe asthma). ... Pirfenidone is under regulatory
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Europe’s cancer community publishes new report on transforming patient care
- Eli Lilly announces $450m investment in US manufacturing site
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- BeiGene’s Brukinsa receives FDA approval for chronic lymphocytic leukaemia
- World Health Organization releases latest set of COVID-19 guidelines
- ASH 2022: bad blood but big advances
- Live Webinar: Streamlining Healthcare Delivery Through Digital Care Journeys
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- Boehringer reports positive phase 2 data for spesolimab in generalised pustular psoriasis
- Microfoundations matter
- 5 ways we’re enhancing our services to support our clients in 2023
- Sanofi/Regeneron’s Dupixent recommended by CHMP for atopic dermatitis in children
- World Health Organization releases latest set of COVID-19 guidelines
- Digital technology: a significant change in healthcare innovation
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- Europe’s cancer community publishes new report on transforming patient care
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- Nicki Muir moves from LEC Healthcare to The Purple Agency
PMHub
Wisepress
Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...
Latest intelligence
- 5 ways we’re enhancing our services to support our clients in 2023
- Fishawack Health CEO Jon Koch explains the new platforms, tools, and services we’re elevating to drive innovation for our clients in 2023....
- ASH 2022: bad blood but big advances
- Five trends from this year’s ASH conference – and why even pop icons can’t compete with the playlist of innovation shaping haematology...
- Virtual Steering Committee & Peer Influence Program
- In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
